European Patients Academy on Therapeutic Innovation: Public Hearings
A public hearing is a crucial forum for the public to voice their concerns on medicine safety and therapeutic effects. It plays a key role in informing the Pharmacovigilance Risk Assessment Committee (PRAC) and enhancing transparency in the regulatory process, empowering EU citizens in medication safety evaluation.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
European Patients Academy on Therapeutic Innovation Aspects of pharmacovigilance: Public hearings
What is a public hearing? European Patients Academy on Therapeutic Innovation A public hearing is a forum to which the public is invited to express its views and concerns on a pre-defined set of questions on issues related to the safety of a particular medicine while also considering its therapeutic effects. It is a channel for the Pharmacovigilance Risk Assessment Committee (PRAC) to take the public s views and concerns into account particularly once all available data and evidence have been assessed, and options for regulatory actions and risk management activities will need to be considered in a wider public health context. 2
Why hold a public hearing? European Patients Academy on Therapeutic Innovation To seek public opinion, suggestions, and recommendations on the acceptability of the risks associated with the medicine or class of medicines concerned; particularly in relation to the medicine s therapeutic effects and any available therapeutic alternatives, as well as the feasibility and acceptability of risk management and minimisation activities To inform the debate of the PRAC, which continues to have the sole responsibility for giving its scientific recommendation on the safety of the medicine concerned. 3
Overall aim: Trust European Patients Academy on Therapeutic Innovation Increase transparency by opening up the scientific evaluation process Empower EU citizens by giving them a voice in the evaluation of the safety of medicines Add value to the evaluation process beyond existing channels of stakeholder engagement Improve the public s understanding of the scientific and regulatory process throughout the product s lifestyle 4
PRAC decision to hold a public hearing European Patients Academy on Therapeutic Innovation Proposal for a public hearing Evaluating the need Agreement to hold a public hearing PRAC evaluates the need for a public hearing PRAC agrees to hold a public hearing either by consensus or by majority vote Referral in accordance with Art. 20 of Regulation EC 726/2004; Art. 31 or Art. 107i of Directive 2001/83/EC Proposal to hold a public hearing can be submitted by any PRAC member Content of proposal: Purpose of the public hearing Specific questions on which public opinion should be sought Any additional information as appropriate 5
How to participate in public hearings European Patients Academy on Therapeutic Innovation Participants can attend in person to speak Participants can submit their contributions in writing Participants can watch via a live video stream 6
Who can attend a public hearing? European Patients Academy on Therapeutic Innovation Public hearings are open to all members of the public. For organisational reasons, participants must register in advance. The questions asked by the PRAC to be addressed during the hearing determine the target audience and are expected to be directed to the general public. The PRAC may proactively invite representatives of patients, consumers, healthcare professionals, or researchers with specific expertise. The Marketing Authorisation Holder(s) has the opportunity to present their view(s) to the participants of the public hearing The media may follow the public hearing as observers. 7
Before the hearing (1) European Patients Academy on Therapeutic Innovation Announcement of the public hearing A summary of the safety concerns A list of specific questions Information on date, time, and location Registration information Information on how to submit written contributions Contact email address and phone number Information about live-broadcast/web stream 8
Before the hearing (2) European Patients Academy on Therapeutic Innovation Submitting a request to speak Name and affiliation (for instance, patient, carer, doctor) Name of the organisation/group being represented (if applicable) Contact information Outline of the planned presentation/intervention, specifically how it addresses the questions on which the PRAC is seeking public opinion Declaration of interest pertaining to the medicine(s) to be discussed at the public hearing 9
Before the hearing (3) European Patients Academy on Therapeutic Innovation Review of requests to speak All requests will be reviewed Efforts made to accommodate all speaking requests Speaking requests may e declined only if clearly unrelated to the subject matter of the public hearing Priority to speakers representing groups, organisations, or institutions Confirmation of attendance as a speaker at least 10 days in advance of the public hearing. 10
